Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) represent two families of bowel disorders with a common denominator of significant unmet medical need. The main unmet need in IBD is disease modifying therapies with greater efficacy in order to slow disease progression and maintain remission, particularly for severe patients. The development pipeline is bursting with potential candidates to treat IBD. In comparison, however, the IBS pipeline is relatively dry as drug developers struggle to unwind the complex pathology behind this disorder. The main unmet need in IBS is effective therapies indicated specifically to alleviate the symptoms of this syndrome.
New analysis from Frost & Sullivan's (healthcare.frost.com) Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals research finds that prescription pharmaceuticals indicated for IBD and IBS earned revenues of approximately $4.26 billion in 2011 and estimates this to reach $7.70 billion in 2017. The analysis finds that the growth is aided by an expansion of the market for biologicals and the introduction of efficacious new therapies.
If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers[.]frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.
"Growth opportunities exist for biologicals and other novel agents, particularly for those that justify initiation of therapy earlier in the course of IBD, as well as for first line therapies that incorporate important improvements such as enhanced delivery or administration," noted Frost & Sullivan Life Sciences Senior Industry Analyst Debbie Toscano. "There is also a tremendous need for safe and effective treatments for severe forms of IBS, which affects a very sizeable patient population."
Biological therapies such as tumor necrosis factor (TNF) inhibitors prove very effective in getting and keeping IBD patients in remission. However, these drugs are typically reserved for more severe patients who have tried and failed standard first line therapies such as aminosalicylates and steroids.
"As evidence accumulates supporting first line use of biologics for improved outcomes for patients, tremendous growth opportunity exists if payers and clinicians are willing to adopt the new treatment paradigm," remarked Toscano. "Considerable opportunity also exists to penetrate the largely untouched IBS market, an indication for which the U.S. Food and Drug Administration (FDA) recognizes significant unmet need."
However, knowledge gaps in the underlying pathology of these diseases impede the identification of new drug targets and development of agents with superior efficacy compared to available therapies. Patient adherence to complicated therapeutic regimens can also hinder market uptake.
"The most important success factor for companies is the marketing of safe and effective therapies with a robust clinical history," concluded Toscano. "This will raise awareness and gain the confidence of prescribing gastroenterologists, patients and payers."
Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals is part of the Life Sciences Growth Partnership Service program, which also includes: Global Life Sciences Trends and Opportunities 2012-2015, United States Oncology Drug Delivery Preferences and Opportunities in Cancer Drug Delivery, and The United States Rheumatic Diseases Therapeutics Market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
Connect with Frost & Sullivan on social media, including Twitter, Facebook, SlideShare, and LinkedIn, for the latest news and updates.
About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion | Join Us: Join our community | Subscribe: Newsletter on "the next big thing" | Register: Gain access to visionary innovation
Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals / NBB6-52